- ALX Oncology Holdings Inc at JPMorgan Healthcare Conference TranscriptJan 09, 2024
- ALX Oncology Holdings Inc at UBS BioPharma Conference TranscriptNov 08, 2023
- ALX Oncology Holdings Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 26, 2023
- ALX Oncology Holdings Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2023
- ALX Oncology Holdings Inc Discuss The Initial AML Data From ASPEN-05 - Conference Call TranscriptDec 13, 2022
- ALX Oncology Holdings Inc at Credit Suisse Healthcare Conference TranscriptNov 09, 2022
- ALX Oncology Holdings Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2022
- ALX Oncology Holdings Inc SITC 2021 Conference Call TranscriptNov 09, 2021
- ALX Oncology Holdings Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 08, 2021
- ALX Oncology Holdings Inc to Discuss New Data from ASPEN-01 and the Phase 1b Study of ALX148 Call TranscriptJul 06, 2021
- ALX Oncology Holdings Inc Annual Shareholders Meeting TranscriptJun 10, 2021
- ALX Oncology Holdings Inc at Jefferies Healthcare Conference (Virtual) TranscriptJun 02, 2021
- ALX Oncology Holdings Inc at UBS Global Healthcare Virtual Conference TranscriptMay 24, 2021
- ALX Oncology Holdings Inc at H C Wainwright Global Life Sciences Conference (Virtual) - Pre-Recorded Fireside Chat TranscriptMar 09, 2021
- ALX Oncology Holdings Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2021
- ALX Oncology Holdings Inc at Jefferies Virtual London Healthcare Conference TranscriptNov 19, 2020
ALX Oncology Holdings Inc Discuss The Initial AML Data From ASPEN-05 - Conference Call Transcript
Good morning, and thank you for dialing in to today's conference call. I'm Jeanne Jew, Chief Business Officer of ALX Oncology. Today's call will focus on clinical data with Evorpacept, our next-generation CD47 myeloid checkpoint inhibitor from the ASPEN-05 Phase Ia dose escalation portion of the trial in AML presented at the American Society of Hematology Annual Meeting, or ASH, on December 12. A slide deck for this webcast is available on our website in the Investors Events section.
Dr. Abraham Fong, Executive Medical Director at ALX Oncology will discuss the background and biological rationale for exploring Evorpacept in combination with venetoclax and azacitidine in patients with AML. We are also privileged to be joined today by Dr. Harry Erba, Director of the Leukemia Program in the division of Hematological Malignancies at Duke University, North Carolina, who will discuss the initial dose escalation portion of the clinical trial data in patients with AML administered Evorpacept in combination with venetoclax and azacitidine.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)